Hiv Vaccine Articles & Analysis: Older
5 articles found
Due to the flexibility of this class of vaccines in developing vaccines against highly variable pathogens, many vaccine candidates are currently in development, including COVID-19 (95 candidates), influenza (24), and HIV (21). ...
NLS) have provided the following observations: Mice vaccinated with HSV-2 0?NLS showed an improved antibody response compared to vaccination with a subunit vaccine candidate, Mice immunized with HSV-2 ...
Two earlier reported studies indicated the beneficial clinical effects of THIVAC, a therapeutic HIV vaccine derived from the blood of HIV-positive donors. However, in those studies no stringent statistical analysis to support the beneficial clinical outcome was attempted. ...
India has more than 5 million people infected with HIV-1 and this number is likely to increase in coming years. It is estimated that by the turn of this decade more than 10 million people would have been infected with this virus. ...
These peptides are linear or branched, single sequenced or multi-epitopic, mostly representative of V3 and/or gp41 regions of HIV-1 envelope and when used as ELISA antigens, recognise human or simian retrovirus-induced antibodies. This review details the efficacy of envelope-based synthetic peptides as antigens in HIV diagnostic assays, including those originally ...